JP2024543134A - 修飾されたタンパク質又はポリペプチド - Google Patents

修飾されたタンパク質又はポリペプチド Download PDF

Info

Publication number
JP2024543134A
JP2024543134A JP2024531051A JP2024531051A JP2024543134A JP 2024543134 A JP2024543134 A JP 2024543134A JP 2024531051 A JP2024531051 A JP 2024531051A JP 2024531051 A JP2024531051 A JP 2024531051A JP 2024543134 A JP2024543134 A JP 2024543134A
Authority
JP
Japan
Prior art keywords
single variable
immunoglobulin single
variable domain
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543134A5 (https=
Inventor
楠 王
暁峰 楊
偉 張
志亮 曹
浩 葉
余紅 沈
成 廖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Shengdi Pharmaceutical Co Ltd
Original Assignee
Shanghai Shengdi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Shengdi Pharmaceutical Co Ltd filed Critical Shanghai Shengdi Pharmaceutical Co Ltd
Publication of JP2024543134A publication Critical patent/JP2024543134A/ja
Publication of JP2024543134A5 publication Critical patent/JP2024543134A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024531051A 2021-11-29 2022-11-29 修飾されたタンパク質又はポリペプチド Pending JP2024543134A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111429892.3 2021-11-29
CN202111429892 2021-11-29
PCT/CN2022/134923 WO2023093899A1 (zh) 2021-11-29 2022-11-29 经修饰的蛋白或多肽

Publications (2)

Publication Number Publication Date
JP2024543134A true JP2024543134A (ja) 2024-11-19
JP2024543134A5 JP2024543134A5 (https=) 2026-03-27

Family

ID=86538884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531051A Pending JP2024543134A (ja) 2021-11-29 2022-11-29 修飾されたタンパク質又はポリペプチド

Country Status (6)

Country Link
US (1) US20250026842A1 (https=)
EP (1) EP4435002A4 (https=)
JP (1) JP2024543134A (https=)
CN (1) CN118339179A (https=)
TW (1) TW202330596A (https=)
WO (1) WO2023093899A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024114676A1 (zh) 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
SG10201805064SA (en) * 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RS55775B2 (sr) * 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP4707303A2 (en) * 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains
JP7001474B2 (ja) * 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
NO2768984T3 (https=) * 2015-11-12 2018-06-09
CN113621065B (zh) * 2021-08-30 2023-08-01 武汉海沙百得生物技术有限公司 靶向4-1bb的全人源抗体及其制备方法和应用

Also Published As

Publication number Publication date
WO2023093899A1 (zh) 2023-06-01
US20250026842A1 (en) 2025-01-23
EP4435002A1 (en) 2024-09-25
CN118339179A (zh) 2024-07-12
EP4435002A4 (en) 2025-03-26
TW202330596A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
JP7773981B2 (ja) 新型ポリペプチド複合物
CA3205006A1 (en) Antibody variable domains that bind il-4r
JP2018536401A (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
IL303174A (en) Multispecific antibodies with specificity for IL-4R and IL-31
US20250051467A1 (en) Fap/cd40 binding molecule and medicinal use thereof
CA3231320A1 (en) Protein specifically binding to pd-1 and pharmaceutical use thereof
JP2026507108A (ja) Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及びその医薬的使用
JP2024531900A (ja) 新規の抗ｓｉｒｐａ抗体
TW202229337A (zh) 犬抗體變異體
EP4628507A1 (en) Cldn18.2/4-1bb binding protein and medical use thereof
US20250026842A1 (en) Modified protein or polypeptide
KR20250153801A (ko) Il-36r 결합 단백질 및 이의 의학적 용도
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途
WO2025103451A1 (zh) Trgv9结合蛋白及其医药用途
EP4019090A1 (en) Antibody variable domains that bind il-4r
CA3274166A1 (en) Cldn18.2/4-1bb binding protein and medical use thereof
WO2026056998A1 (zh) Gipr结合分子及医药用途
EP4650366A1 (en) Tgfbeta1 binding molecule, garp-tgfbeta1 binding molecule and medical use thereof
CN122003438A (zh) Enpp3和cd3结合剂及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260318